Zolinza
(vorinostat)ApprovedSmall molecule
Vorinostat is used to treat a type of cancer called cutaneous T-cell lymphoma, which affects skin cells and causes lesions or tumors on the skin.[2] Zolinza is currently approved and in use across 83 indications[4].[1]
Zolinza is one of 1556 small molecule programs targeting Glioma. It is currently in Approved.
83
Indications
230
Total Trials
20
Active Trials
1,555
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
3
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 83 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Zolinza
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Halaven
EisaiPreclinical
DATROWAY
Daiichi SankyoPreclinical
Zolymbus
AbbViePreclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Aquasol E
NNational Eye Institute (NEI)
Preclinical
Paracetamol
GSKPreclinical
Metfomin
UUniversity of Texas Southwestern Medical Center
Preclinical
Diuretic
RReprieve Cardiovascular, Inc
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Q4 2026
Phase 1Not yet recruiting
Safety and Efficacy
NCT07150026
Phase 1Not yet recruiting
Rett Syndrome
NCT07150013
Phase 1Active, not recruiting
Allogeneic Hematopoietic Cell Transplant
NCT03843528
Phase 1Active, not recruiting
Breast Cancer
NCT03742245
Phase 1/2Active, not recruiting
Myelodysplastic Syndromes
NCT00392353
Clinical
Trials by Indication[1]
Lymphoma18 trials
Show 15 more trials
Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma
Completed·—·Phase 2·NCT00720876·30 enrolled
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Terminated·—·Phase 1·NCT01116154·30 enrolled
Multiple Myeloma13 trials
Show 10 more trials
Breast Cancer12 trials
Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer
Completed·—·Phase 1·NCT01084057·56 enrolled
Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer
Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00616967·68 enrolled
Show 9 more trials
Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy
Completed·—·Phase 1/2·NCT00574587·55 enrolled
Non-Small Cell Lung Cancer9 trials
Show 6 more trials
Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)
Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT02638090·120 enrolled
Advanced Cancer5 trials
94 more indications
Glioblastoma Multiforme5 trials
Cutaneous T-cell lymphoma4 trials
Glioblastoma4 trials
Acute Lymphoblastic Leukemia4 trials
Neuroblastoma4 trials
Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
No longer available·—··NCT01838187
Pancreatic Cancer3 trials
Myelodysplastic Syndrome3 trials
Acute Myeloid Leukemia3 trials
Patients With Advanced Solid Tumors3 trials
Relapsed or Refractory2 trials
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
Active, not recruiting·—·Phase 1·NCT03150329·52 enrolled
Glioma2 trials
HIV2 trials
Trial2 trials
Soft Tissue Sarcoma2 trials
Diffuse Intrinsic Pontine Glioma2 trials
Colorectal Cancer2 trials
Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT02316340·42 enrolled
Mycosis Fungoides2 trials
Graft Vs Host Disease2 trials
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
Active, not recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT03842696·43 enrolled
Melanoma2 trials
Patients With Solid Tumors2 trials
Refractory Solid Tumors2 trials
Chronic Lymphocytic Leukemia2 trials
Prostate Cancer2 trials
Malignant Glioma2 trials
Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients
Completed·—·Phase 2·NCT01738646·48 enrolled
Chemotherapy2 trials
HIV-1 infection2 trials
Unresectable Solid Tumor2 trials
T-cell non-Hodgkin lymphoma2 trials
Diffuse Large B-Cell Lymphoma2 trials
Myelodysplastic Syndromes2 trials
Kidney Cancer2 trials
Lung Cancer2 trials
HIV infection2 trials
Metastatic Prostate Cancer1 trial
Locally Advanced1 trial
Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC
Withdrawn·—·Phase 2·NCT05608369
Pembrolizumab1 trial
Mantle Cell Lymphoma1 trial
Leukemia1 trial
Ovarian Carcinoma1 trial
Advanced Malignancies1 trial
Adenocarcinoma1 trial
Metastatic Colorectal Cancer1 trial
Adenoma1 trial
Von Hippel-Lindau Disease1 trial
Locally Advanced Solid Tumor1 trial
Ovarian Cancer1 trial
Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer
Terminated·—·Phase 1/2·NCT00910000·15 enrolled
T Cells1 trial
Hematological Malignancies1 trial
Adenoid Cystic Carcinoma1 trial
Metastatic Head and Neck Cancer1 trial
Hematologic Malignancies1 trial
Acute Leukemia1 trial
Salivary Gland Cancer1 trial
Advanced Cancers1 trial
Lymphoid Malignancies1 trial
Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies
Completed·—·Phase 1·NCT00691210·40 enrolled
Viremia1 trial
Recurrent or Metastatic1 trial
Malignant Pleural Mesothelioma1 trial
Ductal Carcinoma in Situ1 trial
Chronic Myelogenous Leukemia1 trial
High Risk1 trial
Advanced NSCLC1 trial
Niemann-Pick disease1 trial
Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1
Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 1/2·NCT02124083·12 enrolled
Primary Peritoneal Cavity Cancer1 trial
Solid Malignancies1 trial
Safety and Efficacy1 trial
Combination Therapy1 trial
Rett syndrome1 trial
Intestinal Cancer1 trial
Central Nervous System1 trial
Allogeneic Hematopoietic Cell Transplant1 trial
Radiation Therapy1 trial
Sickle Cell Disease1 trial
Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease
Terminated·—·Phase 2·NCT01000155·5 enrolled
Hematologic Cancer1 trial
Thyroid Cancer1 trial
Clinical Trial1 trial
A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer
Completed·—·N/A·NCT00735826·10 enrolled
Advanced Sarcoma1 trial
Regulatory
FDA Approval Timeline[5]
Oct 6, 2006
ZOLINZA
NDA NDA021991
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Zolinza drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for vorinostat. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]